• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Emergent BioSolutions downgraded by The Benchmark Company

    11/10/22 11:03:51 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EBS alert in real time by email
    The Benchmark Company downgraded Emergent BioSolutions from Buy to Hold
    Get the next $EBS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EBS

    DatePrice TargetRatingAnalyst
    12/30/2024$15.00Buy
    H.C. Wainwright
    8/22/2024$16.00Buy
    Rodman & Renshaw
    3/7/2024$5.00Hold → Buy
    The Benchmark Company
    11/20/2023Underweight
    JP Morgan
    8/29/2023Buy → Hold
    The Benchmark Company
    4/10/2023$22.00Hold → Buy
    The Benchmark Company
    3/17/2023$23.00 → $9.00Neutral → Underweight
    JP Morgan
    11/10/2022Buy → Hold
    The Benchmark Company
    More analyst ratings

    $EBS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Papa Joseph C bought $349,800 worth of shares (60,000 units at $5.83), increasing direct ownership by 21% to 342,500 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      5/15/25 4:02:40 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Emergent BioSolutions with a new price target

      H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00

      12/30/24 7:24:57 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Emergent BioSolutions with a new price target

      Rodman & Renshaw initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $16.00

      8/22/24 7:22:39 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions upgraded by The Benchmark Company with a new price target

      The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $5.00

      3/7/24 10:14:18 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Quality & Ethics, and CPL Glessner Coleen covered exercise/tax liability with 1,249 shares, decreasing direct ownership by 0.71% to 174,927 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      6/10/25 4:12:36 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Bioservices Hartzel William covered exercise/tax liability with 1,167 shares, decreasing direct ownership by 1% to 107,955 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      6/10/25 4:12:45 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Products Business Williams Paul Anthony covered exercise/tax liability with 464 shares, decreasing direct ownership by 0.54% to 85,871 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      6/10/25 4:12:27 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    SEC Filings

    See more
    • Emergent BioSolutions Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Emergent BioSolutions Inc. (0001367644) (Filer)

      6/24/25 4:09:39 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Emergent BioSolutions Inc. (0001367644) (Filer)

      5/23/25 4:06:03 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Emergent BioSolutions Inc.

      144 - Emergent BioSolutions Inc. (0001367644) (Subject)

      5/23/25 4:04:26 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care